One of the most extensively studied peptides in modern metabolic research, Semaglutide has been the subject of the STEP, SUSTAIN, and PIONEER clinical trial programs
Support local journalism
Why Employers Are Zeroing In On GLP-1s The numbers tell the story: 40% of US adults are living with obesity, with projections closer to 50% by 2030 Employers spend $6,472 more per year on employees with obesity than on healthy-weight employees across medical, productivity, disability, and workers comp Individuals who use GLP-1s can lose between 2.5% and 20% of their initial body weight when taking the medication as instructed Employers want to support prevention, not wait until employees are sicker to qualify for care
Even when death was included in the endpoint, the benefits remained significant (HR 0.51, P = 0.001), underscoring the lasting CV protection of early intensified intervention in patients with T2DM and microalbuminuria
Whether youre looking to enhance cognitive performance or restore balance after burnout, peptide therapy at Revital Trichology & Wellness can help you achieve sharper focus, better emotional balance, and renewed brain vitality.
Benchmarking and Preclinical Evaluation of Drug Candidates Preclinical drug and target discovery for obesity is a highly competitive area
